Target intelligence / Profile preview

Modulator of smoothened protein (MOSMO)

Target
MOSMO
Molecular classification
Other (membrane tetraspan protein; not a GPCR, enzyme, or classic receptor)
01

Overview

MOSMO is a membrane tetraspan protein that functions as a negative regulator of the Hedgehog signaling pathway by promoting the internalization and degradation of the smoothened (SMO) transducer, consequently downregulating pathway activation. It plays essential roles in embryonic development, particularly in craniofacial and neural tube formation, with deficiency or inactivation leading to congenital malformations. MOSMO is distinct from the Smoothened receptor itself; rather, it modulates SMO activity and thereby influences Hedgehog signaling output[5][7].

Other names
ATTHOGC16orf52Attenuator of HedgehogBC030336uncharacterized protein C16orf52modulator of smoothened protein
02

Mechanism of action

Drugs targeting the Hedgehog pathway (e.g., Smoothened inhibitors) might act indirectly on the pathway influenced by MOSMO, but no drugs directly targeting MOSMO have been described. MOSMO acts by promoting internalization and degradation of Smoothened, thereby reducing pathway activation[5].

03

Biological functions

Negative regulation of smoothened signaling pathwayRegulation of neuron differentiationRegulation of protein stabilityChordate embryonic developmentEmbryonic limb morphogenesis
04

Disease associations

Developmental disorders (e.g., congenital craniofacial malformations, linked to 16p12.1 chromosomal deletion syndrome encompassing the MOSMO locus)Potential candidate for unexplained human congenital craniofacial malformations
05

Safety considerations

No targeted pharmacological safety data; however, loss-of-function can produce craniofacial malformations[5], indicating potential developmental toxicity risk for therapeutic interventions.
06

Biomarkers

None established for MOSMO specifically; alterations or deletions involving the MOSMO locus (such as 16p12.1 deletions) may be considered a candidate biomarker for some craniofacial syndromes[5].

Beyond the preview

Go deeper on Modulator of smoothened protein (MOSMO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modulator of smoothened protein (MOSMO).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call